First quarter 2026 – Strategic transformation and strengthening financial resilience

Elkem reported Q1 2026 EBITDA of NOK 249 million, down sharply from NOK 710 million a year earlier, with the decline mainly attributed to production curtailments at multiple Norwegian plants. The company expects to complete the sale of its Silicones division today, and says the divestment will sharpen strategic focus and capital allocation. Elkem also plans a guaranteed equity offering of NOK 1,500 million plus a subsequent repair offering, with additional fully underwritten financing secured.

Analysis

This is less a single-quarter earnings miss than a forced strategic reset: the combination of asset sale proceeds plus equity issuance should de-lever the balance sheet, but it also signals management is prioritizing liquidity and covenant headroom over near-term ROE. The market is likely to underappreciate the sequencing risk here — when a company sells a structurally higher-margin division and simultaneously raises equity, the remaining industrial footprint can rerate lower on quality-of-earnings even if headline leverage improves.

The second-order winner is likely Elkem’s direct competitors in silicones and specialty materials, who may absorb displaced customer relationships before the divestment fully closes. But the bigger competitive dynamic is on the cost side: production curtailments in Norway imply Elkem’s marginal cost curve is still vulnerable to regional energy/input volatility, which can keep EBITDA recovery muted for several quarters unless operating rates normalize quickly. If the curtailments persist, the post-transaction story shifts from “focus and simplification” to “shrinking core business with limited operating leverage.”

The key risk window is the next 1-3 months, not the next year: closing mechanics, deal proceeds, and the equity raise will determine whether this becomes a cleansing recapitalization or a dilutive overhang. The repair offering reduces some technical pressure, but it also creates a supply overhang in the stock if retail holders chase the rights economics. Any evidence that curtailments are reversible or that underlying end-market demand is stabilizing could trigger a relief rally, but absent that, the stock likely trades as a de-risking special situation rather than a cyclical recovery.

The contrarian angle is that the market may be focusing too much on dilution and too little on optionality from a cleaner structure. If the remaining business has better capital intensity and less earnings volatility than feared, the equity could outperform once the sell-down and recap are completed. That said, the bar is high: investors will need proof that post-divestment EBITDA is not just smaller, but more durable and less exposed to plant-level interruptions.

Key Decisions for Investors

• Avoid chasing the equity into the offering: wait until the guaranteed placement and repair terms clear, then reassess 2-4 weeks post-close for a cleaner entry if the stock sells off into technical pressure.
• If liquid and borrowable, consider a tactical short only into the rights/repair offering window, targeting 5-10% downside from dilution overhang; cover once placement risk is removed.
• For a relative-value expression, pair long a higher-quality Nordic materials name with short Elkem to isolate balance-sheet repair risk versus operational stability over the next 1-3 months.
• If the post-divestment pro forma leverage drops meaningfully, pivot to a medium-term long only on confirmation of stable operating rates; otherwise keep exposure limited to event-driven trading rather than core holding.